ORION CORPORATION MANAGERS’ TRANSACTIONS 23 JULY 2021 at 3:00 p.m. EEST
Orion Corporation: Managers’ transactions – Liisa Hurme
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion Oyj – Managers’ Transactions
____________________________________________
Person subject to the notification requirement
Name: Aino Anna Liisa Hurme
Position: Other senior manager
(X) Legal person
Issuer: Orion Oyj
LEI: 74370029VAHCXDR7B745
Notification type: INITIAL NOTIFICATION
Reference number: 74370029VAHCXDR7B745_20210723101124_5
____________________________________________
Transaction date:
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009014377
Nature of the transaction: DISPOSAL
Transaction details
(1): Volume: 1,000 Unit price: 35.01 EUR
(2): Volume: 1,000 Unit price: 35.008 EUR
(3): Volume: 5,000 Unit price: 35.1 EUR
(4): Volume: 5,700 Unit price: 35.3 EUR
Aggregated transactions
(4): Volume: 12,700 Volume weighted average price: 35.17543 EUR
Orion Corporation
Timo Lappalainen
President and CEO |
Olli Huotari
SVP, Corporate Functions |
Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
http://www.orion.fi/en
http://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion’s net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.
CHICAGO--(BUSINESS WIRE)--The Board of Directors of GE HealthCare Technologies Inc. (Nasdaq: GEHC) today declared a…
Multi-modality showcase brings hands-on experience to care delivery for a wide range of vascular diseases…
Experienced global CFO adds depth in financial strategy and operating excellence to Smartsheet boardBELLEVUE, Wash.--(BUSINESS…
The Centers for Medicare & Medicaid Services revise the National Coverage Determination of allogeneic hematopoietic…
Feedback provides greater clarity on regulatory requirements for planned Phase 2b trial BOTHELL, Wash. (March…
DUBLIN--(BUSINESS WIRE)--The "Global Medical Device Connectivity Market: Analysis By Product & Services, By Technology, By…